Shingles vaccine trial aims to protect vulnerable patients

NCT ID NCT05879419

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a strong immune response. The goal is to prevent shingles without worsening the underlying rheumatic condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Recombinant Herpes Zoster Vaccine (Shingrix)
What this could lead to
If successful, this could show that the Shingrix vaccine is safe and effective for people with autoimmune rheumatic diseases, reducing their high risk of shingles.
What could go wrong
This is an early-stage study in a specific patient group, and results may not apply to all. The vaccine could cause flares or have reduced effectiveness due to immunosuppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHÇET DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.